Neoadjuvant Chemotherapy

In cases where breast cancer is detected, chemotherapy should be administered before surgery. It has been shown that by reducing the distribution of cancer within the body, cancer can be better controlled and disease-free life can be extended in well-ed patients.

It is preferred when the cancerous tissue detected in the breast is large, although small, it involves the skin, nipple, muscle tissues behind the breast, and when metastases are detected in the armpit lymph nodes or distant parts of the body. In conditions where the tumor grows so much or comes into contact with surrounding tissues, it is thought to come into contact with blood.

If the tumor is 1 cm or less, the risk of spread to the body through blood is considered to be 8%, while if there is a 3cm sized mass or metastasis in the lymph nodes or if skin or muscle tissue is involved, it is considered to have spread to the body by blood at around 35%.

If there is distant organ metastasis, spread through blood is 100%. Neoadjuvant Chemotherapy is a preferred approach today, as patients under the age of 70 can benefit from Neoadjuvant Chemotherapy and their healthy life span will be extended.

In addition, with modern treatment protocols, it is preferred for the patient to receive hormone therapy (Neoadjuvant Hormonotherapy) before surgery is planned, even in hormone-based tumors and in conditions where the patient is older, as it ensures the shrinkage of the tumor tissue, facilitates the surgery and increases disease-free survival.

In order to adapt to lobectomy and perform breast-conserving surgery, it is preferred that the patient first receive chemotherapy in collaboration with the oncologist.